Chennai-based Caplin Point Laboratories has earmarked ₹500-550 crore towards capital expenditure (capex). It includes expansion of existing capacities, additional manufacturing sites to widen the product range, and to achieve backward integration for a majority of products.Established in 1990, the Chennai-based drugmaker began with manufacturing a range of ointments, creams and other external applications. The company has since expanded into manufacture of pharmaceutical formulations and therapeutics both under generic and branded categories. Its product portfolio includes tablets, capsules, injections, liquid orals, and ointments and creams.Currently, Caplin Point and its...
Chennai-based Caplin Point Laboratories has earmarked ₹500-550 crore towards capital expenditure (capex). It includes expansion of existing capacities, additional manufacturing sites to widen...